Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
etiprednol dicloacetate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| etiprednol dicloacetate | DRUG | - |
* Must have active confirmed Crohn's disease with CDAI \> 220 and \< 400. * Otherwise healthy.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Etiprednol dicloacetate is an investigational small molecule being studied for the treatment of Crohn's Disease, a type of inflammatory bowel disease. It is being developed by Teva Pharmaceutical Industries Limited (TEVA) and is currently in Phase 2 clinical development.
The molecular target of etiprednol dicloacetate has not been disclosed. It is a small molecule being investigated for its potential therapeutic effect in Crohn's Disease, but the specific biological pathway it acts on has not been publicly specified.
Etiprednol dicloacetate is being developed by Teva Pharmaceutical Industries Limited, a global pharmaceutical company traded on the NYSE under the ticker symbol TEVA. The drug is currently in Phase 2 clinical trials for Crohn's Disease.
Etiprednol dicloacetate is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial for the treatment of Crohn's Disease has been completed.
Etiprednol dicloacetate has been studied in one completed Phase 2 clinical trial with the identifier NCT00035503, titled 'Multicenter Trial For Patients With Acute Crohn's Disease'. The trial was conducted in the United States and Canada and enrolled adult patients aged 18 years and older.
No alternative names for etiprednol dicloacetate have been disclosed. The drug is identified by its chemical name and is being developed under this designation by Teva Pharmaceutical Industries Limited for Crohn's Disease.